Compared to cancer patients who received therapies other than anti-PD-1 antibodies or healthy control individuals, patients with cancer receiving anti-PD-1 antibodies exhibited a 2.6-fold expansion of ICOS+CD38+ Tfh cells on average one week after vaccination (Fig. 2). Here, PDCD1 is linked to cancer.